|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0027627,
umls-concept:C0030705,
umls-concept:C0149925,
umls-concept:C0253023,
umls-concept:C0871261,
umls-concept:C1533716,
umls-concept:C1539477,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1749467,
umls-concept:C1999230,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-4-14
|
|
pubmed:abstractText |
The Fas/Fas ligand (FasL) system is a major regulator of apoptosis. Chemotherapeutic drugs have been shown to induce Fas expression on the surface of lung cancer cells, and cancer cell apoptosis. However, this mechanism is not considered to be associated with Fas expressed on lung cancer cells. Soluble Fas and FasL concentrations are reportedly elevated in the peripheral blood of patients with lung cancer, but the roles of circulating soluble Fas and FasL in that disease have not been clarified.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0361-090X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-80
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15829378-Aged,
pubmed-meshheading:15829378-Aged, 80 and over,
pubmed-meshheading:15829378-Antigens, CD95,
pubmed-meshheading:15829378-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15829378-Carcinoma, Small Cell,
pubmed-meshheading:15829378-Case-Control Studies,
pubmed-meshheading:15829378-Disease Progression,
pubmed-meshheading:15829378-Fas Ligand Protein,
pubmed-meshheading:15829378-Female,
pubmed-meshheading:15829378-Humans,
pubmed-meshheading:15829378-Lung Neoplasms,
pubmed-meshheading:15829378-Male,
pubmed-meshheading:15829378-Membrane Glycoproteins,
pubmed-meshheading:15829378-Middle Aged,
pubmed-meshheading:15829378-Prognosis,
pubmed-meshheading:15829378-Treatment Outcome,
pubmed-meshheading:15829378-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
|
|
pubmed:affiliation |
Department of Respiratory Medicine, Nagoya University School of Medicine 65, Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan.
|
|
pubmed:publicationType |
Journal Article
|
